174 related articles for article (PubMed ID: 36636443)
1. Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy.
Lee C; Drobni ZD; Zafar A; Gongora CA; Zlotoff DA; Alvi RM; Taron J; Rambarat PK; Schoenfeld S; Mosarla RC; Raghu VK; Hartmann SE; Gilman HK; Murphy SP; Sullivan RJ; Faje A; Hoffmann U; Zhang L; Mayrhofer T; Reynolds KL; Neilan TG
JACC CardioOncol; 2022 Dec; 4(5):660-669. PubMed ID: 36636443
[TBL] [Abstract][Full Text] [Related]
2. Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded Outcomes.
Kondapalli L; Hsia J; Miller R; Flaig TW; Bonaca MP
JACC CardioOncol; 2022 Dec; 4(5):649-656. PubMed ID: 36636437
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
5. Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy.
Schiffer WB; Deych E; Lenihan DJ; Zhang KW
Int J Cardiol; 2021 Jan; 322():177-182. PubMed ID: 32800916
[TBL] [Abstract][Full Text] [Related]
6. [Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery].
Yang BG; Yu XP; Chen F; Lyu SZ; Li Q; He JQ; Yuan F
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jan; 45(1):19-25. PubMed ID: 28100341
[No Abstract] [Full Text] [Related]
7. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
8. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
9. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
Kehl KL; Yang S; Awad MM; Palmer N; Kohane IS; Schrag D
Cancer Immunol Immunother; 2019 Jun; 68(6):917-926. PubMed ID: 30877325
[TBL] [Abstract][Full Text] [Related]
10. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations.
Chiang CH; Chiang CH; Ma KS; Hsia YP; Lee YW; Wu HR; Chiang CH; Peng CY; Wei JC; Shiah HS; Peng CM; Neilan TG
Jpn J Clin Oncol; 2022 Dec; 52(12):1389-1398. PubMed ID: 36208180
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting.
Moey MYY; Tomdio AN; McCallen JD; Vaughan LM; O'Brien K; Naqash AR; Cherry C; Walker PR; Carabello BA
JACC CardioOncol; 2020 Sep; 2(3):491-502. PubMed ID: 34396256
[TBL] [Abstract][Full Text] [Related]
12. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
15. B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial.
Redfors B; Chen S; Crowley A; Ben-Yehuda O; Gersh BJ; Lembo NJ; Brown WM; Banning AP; Taggart DP; Serruys PW; Kappetein AP; Sabik JF; Stone GW
Circulation; 2018 Jul; 138(5):469-478. PubMed ID: 29666071
[TBL] [Abstract][Full Text] [Related]
16. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
17. Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management:
Suero-Abreu GA; Zanni MV; Neilan TG
JACC CardioOncol; 2022 Dec; 4(5):598-615. PubMed ID: 36636438
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial.
Dangas GD; Farkouh ME; Sleeper LA; Yang M; Schoos MM; Macaya C; Abizaid A; Buller CE; Devlin G; Rodriguez AE; Lansky AJ; Siami FS; Domanski M; Fuster V;
J Am Coll Cardiol; 2014 Sep; 64(12):1189-97. PubMed ID: 25236509
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Coronary Artery Bypass Grafting and Drug-Eluting Stent Implantation in Patients With Chronic Kidney Disease: A Propensity Score Matching Study.
Li Y; Hou X; Liu T; Xu S; Huang Z; Xu X; Dong R
Front Cardiovasc Med; 2022; 9():802181. PubMed ID: 35433853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
